Literature DB >> 19946694

The threat of misdiagnosis of primary osteosarcoma over the age of 60: a series of seven cases and review of the literature.

Patrick Sadoghi1, Andreas Leithner, Heimo Clar, Mathias Glehr, Christine Wibmer, Koppany Bodo, Franz Quehenberger, Reinhard Windhager.   

Abstract

BACKGROUND: Osteosarcoma is the most common, non-haematopoietic, primary malignant bone tumour with an incidence of 0.3-0.5 per 100,000. There is some discrepancy in literature concerning the peaks of incidence of osteosarcoma. Some describe only one peak which arises in adolescence, whilst others report a bimodal age distribution with a second peak over the age of 60. In this retrospective study, we evaluated osteosarcoma patients over age 60 treated at our department and reviewed previous studies from the literature. PATIENTS AND METHODS: Sixty-four patients (40 male, 24 female) with a mean age of 29 years (from 7 to 82) were treated for primary osteosarcomas. At the time of diagnosis, seven patients (two male and five female) were over 60 years of age with a mean follow-up of 46 months after definite diagnosis.
RESULTS: Three out of seven osteosarcomas were primarily radiologically or histologically misdiagnosed, but only one was mistreated with intramedullary nailing at a trauma centre. At last follow-up, two patients had died from the disease, three were alive with disease, and two had no evidence of osteosarcoma.
CONCLUSIONS: We did not find an increased incidence of primary osteosarcoma in the elderly; yet, older patients had a higher rate of misdiagnosis due to untypical radiological findings in combination with longer times from the onset of first symptoms to definite diagnosis. In cases of pathological fracture, it is essential to assess whether it is caused by mechanical stress or a primary or secondary tumour before leading into mistreatment, especially in older patients.

Entities:  

Mesh:

Year:  2009        PMID: 19946694     DOI: 10.1007/s00402-009-1011-9

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  8 in total

1.  Role of β-isomerized C-terminal telopeptides (β-CTx) and total procollagen type 1 amino-terminal propeptide (tP1NP) as osteosarcoma biomarkers.

Authors:  Tu Hu; Qingcheng Yang; Jing Xu; Zhichang Zhang; Nengbin He; Yuzhen Du
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  [Bone metastases treatment strategies].

Authors:  A Leithner; J Friesenbichler; D Andreou; W Maurer-Ertl; P U Tunn
Journal:  Orthopade       Date:  2012-10       Impact factor: 1.087

3.  [Secondary telangiectatic osteosarcoma of the left femur. A case presentation of an unusual course of disease].

Authors:  D Zajonz; M Werner; S Panzert; A S Strübing; S Tiepolt; E Fabsits; P Brandmaier; C-E Heyde; T Prietzel
Journal:  Orthopade       Date:  2014-05       Impact factor: 1.087

4.  Silencing microRNA-27a inhibits proliferation and invasion of human osteosarcoma cells through the SFRP1-dependent Wnt/β-catenin signaling pathway.

Authors:  Yu Mu; Lina Zhang; Xue Chen; Si Chen; Yuanyuan Shi; Junfeng Li
Journal:  Biosci Rep       Date:  2019-06-04       Impact factor: 3.840

5.  Primary osteosarcoma in elderly patients: A report of three cases.

Authors:  Qiang Xu; Tian Gao; Bin Zhang; Jin Zeng; Min Dai
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

6.  Unusual Location of Bone Tumor Easily Misdiagnosed: Distal Radius Osteosarcoma Treated as Osteomyelitis.

Authors:  Muath Mamdouh Mahmod Al-Chalabi; Izzeddin Jamil; Wan Azman Wan Sulaiman
Journal:  Cureus       Date:  2021-11-25

7.  Differentiation of osteosarcoma from osteomyelitis using microarchitectural analysis on panoramic radiographs.

Authors:  Ji-Hun Jung; Kyung-Hoe Huh; Tae-Hoon Yong; Ju-Hee Kang; Jo-Eun Kim; Won-Jin Yi; Min-Suk Heo; Sam-Sun Lee
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

8.  MicroRNA-567 inhibits cell proliferation, migration and invasion by targeting FGF5 in osteosarcoma.

Authors:  Daodong Liu; Chaoju Zhang; Xiaolin Li; Hongmei Zhang; Qixiong Pang; An Wan
Journal:  EXCLI J       Date:  2018-01-15       Impact factor: 4.068

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.